Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

NCT05003986 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Focal Segmental Glomerulosclerosis
Minimal Change Disease
Immunoglobulin A Nephropathy
IgA Vasculitis
Alport Syndrome

Interventions

DRUG: Sparsentan
DRUG: Sparsentan
DRUG: Sparsentan

Sponsor

Travere Therapeutics, Inc.